N-[[4-[2-(3-chloro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide | 198470-78-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[[4-[2-(3-chloro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide
• 英文别名: N-[4-[2-(3-chloro-5-methylphenyl)-4-(trifluoromethyl)imidazol-1-yl]phenyl]sulfonylacetamide
• CAS: 198470-78-9
• 化学式: C₁₉H₁₅ClF₃N₃O₃S
• 分子量: 457.861
• InChiKey: HBJRELCEAUESDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  89.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-[2-(3-Chloro-5-methyl-phenyl)-4-trifluoromethyl-imidazol-1-yl]-benzenesulfonamide 、 乙酰氯 在 乙醚 作用下， 以 溶剂黄146 为溶剂， 反应 5.0h， 以to give 0.23 g (70%) of N-[[4-[2-(3-chloro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide as a white solid的产率得到N-[[4-[2-(3-chloro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide
  参考文献：
  名称：

  Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors

  摘要：

  COX-2抑制剂的前药被描述为在治疗炎症和炎症相关疾病方面有用。

  公开号：

  US20050032851A1

文献信息

• Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
  申请人：G. D. Searle & Co.

  公开号：US05932598A1

  公开（公告）日：1999-08-03

  Prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.

  COX-2抑制剂的前药被描述为在治疗炎症和与炎症相关的疾病方面很有用。
• Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
  申请人：Masferrer L. Jaime

  公开号：US20050187172A1

  公开（公告）日：2005-08-25

  The present invention provides combinations of a Cox-2 inhibitor and a DNA topoisomerase inhibitor and methods of use thereof for preventing and/or treating neoplasia or or a neoplasia-related disorder in a subject.

  本发明提供了一种COX-2抑制剂和DNA拓扑异构酶抑制剂的组合物，以及它们的使用方法，用于预防和/或治疗受试者中的肿瘤或与肿瘤相关的疾病。
• Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
  申请人：Pulaski P. Steven

  公开号：US20050014729A1

  公开（公告）日：2005-01-20

  A method for preventing or treating dermatological disorders and dermatological disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a dermatological treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a dermatological treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.

  一种预防或治疗受试者的皮肤病和与皮肤病相关并发症的方法涉及使用Cox-2抑制剂进行单独治疗或与Cox-2抑制剂和皮肤治疗剂的联合治疗。还描述了包含Cox-2抑制剂和皮肤治疗剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。
• Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
  申请人：Pharmacia Corporation

  公开号：US20040204471A1

  公开（公告）日：2004-10-14

  A method for preventing or treating otic disorders and otic disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and an otic agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and an otic agent. Pharmaceutical compositions and kits for implementing the present method are also described.

  一种用于预防或治疗主体的耳部疾病和耳部疾病相关并发症的方法涉及使用Cox-2抑制剂进行单一疗法或使用Cox-2抑制剂和耳部药剂进行联合疗法。还描述了包含Cox-2抑制剂和耳部药剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。
• Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
  申请人：Pharmacia Corporation

  公开号：US20040220155A1

  公开（公告）日：2004-11-04

  A method is described for providing a steroid-sparing benefit to a subject that is in need of, or that is presently receiving, a corticosteroid, the method comprising administering to the subject a cyclooxygenase-2 inhibitor in combination with a corticosteroid. Therapeutic compositions, pharmaceutical compositions and kits that are useful for implementing the present method are also described.

  描述了一种为需要或目前正在接受皮质类固醇治疗的受试者提供节约类固醇的方法，该方法包括向受试者同时给予环氧合酶-2抑制剂和皮质类固醇。还描述了用于实施该方法的治疗组合物、药物组合物和工具包。